Nykode Therapeutics’ Post

The success of linear mRNA vaccines has set the stage for the next generation of RNA modalities. The rise of these innovations demands conversations about what the future RNA therapeutics regulatory paradigm should look like. On May 2 at 11 am EST, join our Chief Quality & Regulatory Officer, Melanie Cerullo M.S., CQA at Advancing RNA Live for a panel discussion exploring: ➤What an “ideal” RNA therapeutics regulatory paradigm could look ➤ Best practices for working with regulators to usher encoding RNA products into the clinic ➤ Approaches for “platforming” product development. Book your spot today 👇 https://lnkd.in/dYEbe5Zb #DrugDevelopment #RNATherapeutics #mRNA

Looking back on the discussions at the RNA Leaders' Congress in Basel. It was great to see many researchers gathering to discuss advances and challenges in #RNA therapeutics and vaccines. Thanks to the speakers for sharing their insights. As one of the panelists mentioned, I'm eager to see how we address global health challenges by tackling these 3Es: Entry to cells Escape from endosomes Efficacy #RNA #Oligonucleotides #Synthesizers #Biotech

Batista Lab researcher Sophie Giguere, PhD, authored a paper which was published in Science today. The paper, ‘Antibody production relies on the tRNA inosine wobble modification to meet biased codon demand’ found that mRNA encoding antibody genes is enriched with codons recognized by modified tRNA. This codon optimization is accompanied by an increase in tRNAs with complementary modifications, which serves to enhance antibody biosynthesis by ASCs. This discovery could have significant implications for the development of therapeutics and vaccine design in the future. #PressRelease #mRNA #Antibodies #Vaccines #Therapeutics

Novo Nordisk and Korro Bio partner to revolutionize cardiometabolic disease treatment through RNA editing. 16 Sep. 2024. In a groundbreaking move, Novo Nordisk has entered into a $530 million partnership with Korro Bio to leverage their proprietary OPERA™ platform for oligonucleotide-directed RNA edits. This collaboration aims to target undruggable targets in cardiometabolic diseases, opening up new avenues for treatment. This partnership aligns with Novo Nordisk's strategic focus on RNA therapeutics, following their acquisitions of Dicerna ($3.3 billion) and Cardior ($1.1 billion). Additionally, their collaboration with Eleven Therapeutics underscores their commitment to advancing RNA-based therapies. With the potential to address previously intractable diseases, this partnership could significantly impact the lives of millions affected by cardiometabolic conditions. According to Market Research Future the Cardiometabolic Disease Market Size was valued at $125 billion in 2022 and is projected to grow $868 billion by 2032. https://lnkd.in/eDkWri4q https://lnkd.in/e2nquivS https://lnkd.in/ecTjUw2M https://lnkd.in/eCQ8U7Sk #RNAediting #cardiometabolicdisease #biotech #pharma #innovation #partnership

1STRAND Network: You're invited to join the most influential senior executives from the #RNAindustry at the RNA Leaders USA Congress taking place September 4 - 5 in San Diego. ⤵   The event covers the entire scope of RNA developments. From advancing #oligo-based therapeutics to the clinic, progressing #mRNA therapeutics and mRNA cancer vaccine to delving into pioneering next-gen applications of RNA editing, RNA as a target, the dark genome, and non-linear RNAs.    Where we explore and facilitate the key strategic partnerships and investments needed to help accelerate the innovation and commercialization of therapeutics and vaccines. Plus, hear sessions from 1STRAND’s very own experts: Michael Hodges, Christine Esau, Gene Yeo, Pad Chivukula, and Tamar Grossman.   Exciting news for BioPharma & Biotech companies with an active drug pipeline! ➡ #RNALeaders has given us 5 complimentary passes to share with our community. Apply here for a chance to join industry leaders like Novo Nordisk, Alltrna, J&J, and many more. https://lnkd.in/gwAvp9xz   ➡ But the good news doesn't stop there if you are not eligible for a complimentary pass, you can secure your spot today for 15% off using the code 1STRAND15 and join senior leaders and decision-makers from across the industry. https://lnkd.in/grrpPjde   We hope to see you there!

On February 28-29, there is a virtual workshop hosted by #USP on “𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗻𝗴 𝘁𝗼 𝗣𝗮𝘃𝗲 𝘁𝗵𝗲 𝗪𝗮𝘆 𝗳𝗼𝗿 𝗺𝗥𝗡𝗔-𝗯𝗮𝘀𝗲𝗱 𝗩𝗮𝗰𝗰𝗶𝗻𝗲𝘀 𝗮𝗻𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗤𝘂𝗮𝗹𝗶𝘁𝘆”! https://lnkd.in/gG8KVyYf A myriad of promising topics on analytical challenges and technology trends is slated to be discussed by experts from the #mRNA industry and #USP such as: ➡ USP's tools to support mRNA vaccine quality and safety ➡ Analytical challenges and perspectives on the future analysis and characterization of mRNA ➡ An industry consensus on defining CQAs for mRNA/LNP products ➡ Considerations on mRNA products potency testing ➡ Analytical approaches for profiling PolyA tails in mRNA ➡ Effects of Ionizable and Non-Ionizable Excipients on Lyophilized RNA formulations using FTIR/ATR Technology ➡ The analysis of mRNA therapeutics using RNA sequencing We look forward to learning more on the advancement in analytical approaches for ensuring identity, safety, and efficacy of mRNA modalities.

📣 Calling all RNA Targeting Therapeutic Experts Register before Friday, April 19, to save up to $1,200 for the 2nd RNA Assay Development & Screening Summit! Following a huge wave of collaboration and investment in the RNA targeting field, for instance Roche and Remix Therapeutics make an RNA pact, raising another $60million, this meeting returns as the first and only industry dedicated event with 3-days deep diving into the development of sensitive, robust and innovative assays to enable discovery of efficacious small molecule therapeutics.   With 18+ RNA assay and screening experts, including the likes of AstraZeneca, Arrakis Therapeutics, Accent Therapeutics, Inc. , Biogen, AbbVie, NextRNA Therapeutics and many more, the 2nd RNA Assay Development & Screening Summit is an unmissable opportunity to hear the hottest advancements in assay and screening strategies for accurately understanding RNA target structures, validating RNA-small molecule binding and discovering the mechanism of action of RNA-targeting drugs to fast-track potent lead candidates towards the clinic. Secure your seat here 👉 https://ter.li/145crs 👈 #RNA #targeting #smallmolecues #assaydevelopment #screening

Noa Therapeutics joins BIOTECanada as its newest member! Noa Therapeutics is a preclinical biotech company pioneering the development of multimodal therapies. Singular, non-steroidal, small molecules with tunable activity across three inflammatory barrier disease drivers to simplify the course of care for patients in need. Current therapeutics for inflammatory barrier diseases focus on symptom relief, particularly inflammation due to the pathophysiological role of inflammatory cytokines in many diseases. However, addressing individual disease drivers in isolation inherently leads to limited efficacy, resulting in poor patient compliance, and unfortunately serious side effects. This current paradigm leaves patients and physicians cycling through trial-and-error treatment failures. Noa is embarking on a journey to develop breakthrough multimodal therapeutics to wholly address the complexity of immune diseases. Providing singular therapeutic solutions with meaningful outcomes. Read more about Noa Therapeutics here: https://lnkd.in/eEE8yxwD For BIOTECanada’s full membership listing, visit: https://lnkd.in/dvc8X94n #newmember #biotechnology #biotech #canada #ecosystem #innovation  #technology #immune #immunedieases #inflammatorybarrierdiseases #multimodaltherapies #smallmolecule

Our new Bispecific and Multispecific Antibodies Collection, brought to you by Editors Nimish Gera, Li Zhou and Jonathan Sockolosky, is online at mAbs! In this collection, we examine the progress in the bispecific antibody landscape over the past decade, emphasizing their design and high-throughput production. Our specific reviews delve into biparatopic and VHH-based bispecific antibodies. Additionally, this collection highlights developability properties, including format, valency, pharmacokinetics, and hydrophobicity. We express our gratitude to the authors for their valuable contributions and anticipate that this compilation will aid readers and scientists worldwide in advancing life-transforming therapies for patients. #mabs https://lnkd.in/ecnWjNU3

Working on next generation RNA therapeutics? If so, the 3rd Next Generation RNA Therapeutics Summit should be on your radar! See the agenda here: https://ter.li/ufw87q ✨ New companies on the agenda - such as Atomic AI, Circio Holding ASA , Orbital Therapeutics, Sail Biomedicines, Johnson & Johnson and noctuRNA Therapeutics – who have never spoken at this summit before ✨ The Return of The Poster Session – the opportunity for emerging and established drug developers and academics to present amongst key stakeholders to exhibit their novel platforms and recent data ✨ 3 Must-Attend Pre-Conference Workshops – your chance to dive into overcoming targeted delivery challenges to achieve next generation RNA therapeutics’ full therapeutic potential, as well as addressing purification challenges and enabling production of high-quality RNA therapeutics to produce more precise, potent, and safer RNA therapies ✨ Hear 20+ Case Studies from leading biopharma including Strand Therapeutics, Laronde, Pfizer, Capstan Therapeutics and more ✨ Fireside Chat with Sanofi and Rothwell Figg on investment and collaboration opportunities With our introductory early bird offer saving you up to $1,100 if you secure your pass by midnight this Friday, January 26, there's no better time to book your place. See your registration options here: https://ter.li/fj452g #rna #rnatherapeutics #circularRNA #saRNA #selfamplifyingRNA #circRNA #eRNA #tRNA #RNAvaccine #RNAconference #RNAsummit